Syncona Limited Syncona appoints new Directors (0422T)
November 22 2021 - 1:00AM
UK Regulatory
TIDMSYNC
RNS Number : 0422T
Syncona Limited
22 November 2021
Syncona Limited
Dr Julie Cherrington and Dr Cristina Csimma join Board as
Non-Executive Directors
22 November 2021
Syncona Ltd, a leading healthcare company focused on founding,
building and funding a portfolio of global leaders in life science,
announces the appointments of Dr Julie Cherrington and Dr Cristina
Csimma as Non-Executive Directors with effect from 1 February
2022.
Dr Julie Cherrington is an experienced life science executive
with a strong track record in bringing drugs into the clinic and
through to commercialisation, and particular expertise in the
oncology setting. She has previously served as President and Chief
Executive Officer at several biotechnology companies in the US West
Coast, Canada and Australia, most recently at ARCH Oncology and QUE
Oncology, and currently holds non-executive roles at a number of
listed and private biotechnology companies including Mirati
Therapeutics.
Dr Cristina Csimma joins Syncona with nearly 30 years'
experience of drug development, new company formation, value
creation and strategic guidance across a broad range of therapeutic
areas. She also brings significant expertise in venture capital and
the US biotech capital market environment. She is currently
Executive Chair of the clinical-stage drug development firm Forendo
Pharma, which recently entered into a definitive agreement under
which Organon will acquire Forendo Pharma, and also holds
non-executive roles at several other listed and private US-based
biotechnology companies.
Melanie Gee, Chair of Syncona Limited, said: "I am very pleased
to welcome Julie and Cristina to the Syncona Board. I am committed
to ensuring that the Syncona Board has a diverse blend of
expertise, perspectives and backgrounds and I believe Julie and
Cristina substantially add to that. Their appointments broaden the
Board's understanding particularly across the US biotech market and
US private and public capital markets, which are key to
successfully delivering Syncona's strategy."
Martin Murphy, CEO of Syncona Investment Management Limited,
said : "I am delighted that biotech industry professionals of the
calibre of Julie and Cristina are joining the Syncona Board. Both
bring broad experience, particularly across the US market, and I
and the team look forward to both of them sharing their insights as
we seek to deliver treatments that will reach patients and maximise
value for our shareholders."
Julie Cherrington said: "Syncona offers an exciting opportunity
to work with an expert management team in the life science sector
that is seeking to manage and grow a sustainable portfolio of
leading companies operating in areas of highly innovative science.
I look forward to joining the Board and supporting the business to
develop and commercialise the therapies in the Syncona
portfolio."
Cristina Csimma said: "I look forward to joining Syncona's Board
and leveraging my experience in global drug development, company
building and capital raising. The Company's purpose of extending
and enhancing human life by founding and building companies that
can deliver transformational treatments to patients is highly
motivating and I am excited to support them in delivering it."
Disclosures in accordance with LR 9.6.13
In accordance with LR 9.6.13 the following disclosures are
made:
Dr Julie Cherrington is currently a director of Mirati
Therapeutics Inc (NASDAQ: MRTX) and Vaxart Therapeutics, Inc
(NASDAQ: VXRT). She was formerly a director of Rakovina
Therapeutics, Inc (TSXV: RKV).
Dr Cristina Csimma is currently a director of Idera
Pharmaceuticals, Inc (NASDAQ: IDRA) and Palisade Bio, Inc (NASDAQ:
PALI), and was formerly a director of Seneca Biopharma, Inc
(NASDAQ: SNCA) and Juniper Pharmaceuticals, Inc. (NASDAQ:
JNPR).
No further details are required to be disclosed under LR
9.6.13.
[ENDS]
Enquiries
Syncona Ltd
Annabel Clay / Fergus Witt
Tel: +44 (0) 20 3981 7940
FTI Consulting
Ben Atwell / Natalie Garland-Collins / Tim Stamper
Tel: +44 (0) 20 3727 1000
About Syncona
Syncona's purpose is to invest to extend and enhance human life.
We do this by founding and building companies to deliver
transformational treatments to patients in areas of high unmet
need.
Our strategy is to found, build and fund companies around
exceptional science to create a dynamic portfolio of 15-20 globally
leading healthcare businesses for the benefit of all our
stakeholders. We focus on developing treatments for patients by
working in close partnership with world-class academic founders and
management teams. Our balance sheet underpins our strategy enabling
us to take a long-term view as we look to improve the lives of
patients with no or few treatment options, build sustainable life
science companies and deliver strong risk-adjusted returns to
shareholders.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAFFLFLFFLLFBQ
(END) Dow Jones Newswires
November 22, 2021 02:00 ET (07:00 GMT)
Syncona (LSE:SYNC)
Historical Stock Chart
From Apr 2024 to May 2024
Syncona (LSE:SYNC)
Historical Stock Chart
From May 2023 to May 2024